Horizon Introduction. Alex Harris Medical Research Council

Transcription

1 Horizon Introduction Alex Harris Medical Research Council

2 Agenda MRC and Horizon 2020 UK Success Rate (FP7 Health) What is Horizon 2020? The Horizon 2020 Health Challenge NCP support

3 MRC and Horizon 2020 The three main roles the MRC plays in Horizon 2020: 1. Participant 2. NCP for the Health, Demographic Change and wellbeing Challenge (Alex Harris) 3. MRC leads the UK Programme Committee delegation (Mark Palmer)

4 UK Success Rate (FP7 Health) EC Contribution 947m 874m UK organisations have secured 947 million of EU funding for Health research so far! 604m 565m 368m 284m 262m UK GER FRA NED ITA SWE SPA

5 What is Horizon 2020? The new European Union programme for research and innovation for A core part of key European policy initiatives 80bn budget An integrated approach coupling research to innovation Major simplification

6 Three priorities Excellent science Industrial leadership Societal challenges

7 What is Horizon 2020?

8 The Health Challenge Health, demographic change and wellbeing challenge (SC1) Budget = 7.47bn Challenge based approach What to do, but not how to do it (less prescription) Collaborative Multidisciplinary approach - fostering cooperation between sectors Strengthening competitiveness of EU industries - development of new market opportunities

9 The Health Challenge Work Programme Work programme with a 2 year-duration. WP 2014/2015, 2 calls: Personalising health and care call 34 topics - 15 in 2014, 17 in 2015, 2 open in both years Co-ordination activities call 16 topics - 11 in 2014, 5 in 2015 (7 ERA-NET) 1.2billion

10 Unravelling health and disease Determinants, risk factors and pathways of diseases (2014) Determinants and pathways of healthy and active ageing (2014) Systems medicine approaches (2015) Common mechanisms of diseases and potential co-morbidities (2015)

11 From "omics" to prevention Inter-sector cooperation for environment- and healthbased interventions (2015) Translating -omics into prevention and health promotion (2014) Evaluating existing screening and prevention programmes (2014) Control of infectious epidemics through rapid pathogen identification (2014) Vaccine platforms for TB (2014) and HIV (2015)

12 In biomarkers we trust and in novel diagnostic tools In vitro devices, assays and platforms (2014) In vivo medical imaging technologies (2015) Clinical validation of biomarkers (2014, 2015) SME focus

13 Finding the cure and evaluating existing treatments Therapies for non-communicable diseases (2014) and rare diseases (2015) Tools and technologies for advanced therapies (2015) Clinical research on regenerative medicine (2014) Comparing and establishing effectiveness of health interventions in the elderly (2014) and children (2015)

14 Adding more life to our years Service robotics within assisted living environments (2014) Pilot projects on independent living with cognitive impairments (2014) Early risk detection and intervention (2015) Promoting mental wellbeing in the ageing population (2015)

15 The citizen in the centre New models for prevention oriented health and care systems (2014) Piloting personalised medicine in health and care systems (2015) Self-management of health and disease: citizen engagement and mhealth for disease management (2014), patient empowerment supported by ICT (2015) based on predictive computer modelling (2015)

16 The citizen in the centre (2) Public procurement of innovative ehealth services (2015) ICT systems for integrated care (2015) ehealth sectorial inducement prize (2015)

17 Big Data for research Digital representation of health data to improve diagnosis and treatment (2015) Foresight for health policy development and regulation (2014) Advancing bioinformatics for clinical needs (2014) Improve predictive human safety testing (2015) ehealth interoperability (2014)

18 Support for European and International Initiatives European Innovation Partnership on Active and Healthy Ageing Global Alliance for Chronic Diseases (GACD) Diabetes (2014) Joint Programming Initiative 'More Years, Better Life's (2014) Joint Programming Initiative on neurodegenerative diseases (JPND, 2014) Global Research Collaboration for Infectious Disease Preparedness (2014) European Reference Networks (2015)

19 The Health Challenge Strategic Research Initiatives:

20 Innovative Medicines Initiative 2 EU contribution billion For breakthrough vaccines, medicines and treatments For top quality research and innovation with great public health benefits and commercial possibilities compared to IMI: more budget, broader scope and objectives, open to other industry partners

21 EDCTP 2 Bigger EU contribution: 683 million Broader scope: including neglected infectious diseases, all clinical phases, diagnostics and delivery optimisation Longer duration: 10 years

22 Active and Assisted Living (AAL 2) EU contribution: 175 million To increase efficiency of care and give older adults access to more and better ICT based products and services for ageing well Compared to AAL: Use of new instruments eg Innovation Grants, prizes; Alignment with EIP-Active Healthy Ageing

23 NCP support A UK-wide network provided to help you engage with H2020 Dissemination and Awareness Raising (Infodays, seminars, ) General advice on H2020 participation help you to make an informed decision (signposting) Helpline - scientific priorities, calls, participation rules, financial rules, partnering Follow-on advice negotiation stage, reports, cost claims, IPR, project management All advice is confidential, impartial and free

24 NCP support Horizon 2020 Health National Contact Points: Alex Harris Octavio Pernas E mail: octavio.pernas@tsb.gov.uk Phone:

25 Further information Participant portal: European Commission Horizon Official UK Horizon 2020 website: Fit for Health: IMI2 EDCTP2 AAL2